SPIRIT-DEFINE Explanation and Elaboration: Recommendations for Enhancing Quality and Impact of Early Phase Dose-finding Clinical Trials Protocols

Funding: This work is a further extension of the SPIRIT-DEFINE study, which obtained no external funding. The principal investigator (CY) used internal staff resources, together with additional resources from external partners, to conduct this study. The SPIRIT-DEFINE study is a component of the DEFINE project, which also developed the MRC/NIHR funded CONSORT-DEFINE guidance. ICR-CTSU receives programmatic infrastructure funding from Cancer Research UK (C1491/A25351; CTUQQR-Dec22/100004), which has contributed to accelerating the advancement and successful completion of this work.

References

Grayling M, Mander A . Two-Stage Single-Arm Trials Are Rarely Analyzed Effectively or Reported Adequately. JCO Precis Oncol. 2021; 5. PMC: 8691516. DOI: 10.1200/PO.21.00276. View

Exley A, Rantell K, McBlane J . Clinical development of cell therapies for cancer: The regulators' perspective. Eur J Cancer. 2020; 138:41-53. DOI: 10.1016/j.ejca.2020.07.006. View

de Haan R, van Werkhoven E, van den Heuvel M, Peulen H, Sonke G, Elkhuizen P . Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib. BMC Cancer. 2019; 19(1):901. PMC: 6734274. DOI: 10.1186/s12885-019-6121-3. View

Mozgunov P, Knight R, Barnett H, Jaki T . Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study. Int J Environ Res Public Health. 2021; 18(1). PMC: 7796482. DOI: 10.3390/ijerph18010345. View

Goulart B, Clark J, Pien H, Roberts T, Finkelstein S, Chabner B . Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res. 2007; 13(22 Pt 1):6719-26. DOI: 10.1158/1078-0432.CCR-06-2860. View

Suh H, Peck C, Yu K, Lee H . Determination of the starting dose in the first-in-human clinical trials with monoclonal antibodies: a systematic review of papers published between 1990 and 2013. Drug Des Devel Ther. 2016; 10:4005-4016. PMC: 5153257. DOI: 10.2147/DDDT.S121520. View

Cole M, Yap C, Buckley C, Ng W, McInnes I, Filer A . TRAFIC: statistical design and analysis plan for a pragmatic early phase 1/2 Bayesian adaptive dose escalation trial in rheumatoid arthritis. Trials. 2021; 22(1):433. PMC: 8259060. DOI: 10.1186/s13063-021-05384-5. View

Kong A, Good J, Kirkham A, Savage J, Mant R, Llewellyn L . Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the trial protocol. BMJ Open. 2020; 10(3):e033009. PMC: 7076237. DOI: 10.1136/bmjopen-2019-033009. View

Chan A, Tetzlaff J, Gotzsche P, Altman D, Mann H, Berlin J . SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346:e7586. PMC: 3541470. DOI: 10.1136/bmj.e7586. View

10.

Tibbitts J, Cavagnaro J, Haller C, Marafino B, Andrews P, Sullivan J . Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals. Regul Toxicol Pharmacol. 2010; 58(2):243-51. DOI: 10.1016/j.yrtph.2010.06.007. View

11.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View

12.

Dehbi H, OQuigley J, Iasonos A . Controlled backfill in oncology dose-finding trials. Contemp Clin Trials. 2021; 111:106605. DOI: 10.1016/j.cct.2021.106605. View

13.

Harrington J, Wheeler G, Sweeting M, Mander A, Jodrell D . Adaptive designs for dual-agent phase I dose-escalation studies. Nat Rev Clin Oncol. 2013; 10(5):277-88. DOI: 10.1038/nrclinonc.2013.35. View

14.

. International Conference on Harmonisation; Guidance on E16 Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure, and Format of Qualification Submissions; availability. Notice. Fed Regist. 2011; 76(155):49773-4. View

15.

Slingluff Jr C, Petroni G, Chianese-Bullock K, Wages N, Olson W, Smith K . Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63). J Immunother Cancer. 2021; 9(1). PMC: 7825263. DOI: 10.1136/jitc-2020-000934. View

16.

Cohen S, Clowse M, Pardo P, Bhattacharya I, Menon S, Gourley I . Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. Clin Ther. 2016; 38(6):1417-1434.e2. DOI: 10.1016/j.clinthera.2016.03.028. View

17.

Butcher N, Monsour A, Mew E, Chan A, Moher D, Mayo-Wilson E . Guidelines for Reporting Outcomes in Trial Reports: The CONSORT-Outcomes 2022 Extension. JAMA. 2022; 328(22):2252-2264. DOI: 10.1001/jama.2022.21022. View

18.

Iasonos A, OQuigley J . Sequential monitoring of Phase I dose expansion cohorts. Stat Med. 2016; 36(2):204-214. PMC: 4976081. DOI: 10.1002/sim.6894. View

19.

Moreau P, Garfall A, van de Donk N, Nahi H, San-Miguel J, Oriol A . Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022; 387(6):495-505. PMC: 10587778. DOI: 10.1056/NEJMoa2203478. View

20.

Ji Y, Wang S . Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013; 31(14):1785-91. PMC: 3641699. DOI: 10.1200/JCO.2012.45.7903. View